Genentech attempts to keep Avastin's breast cancer indication

08/7/2011 | Genetic Engineering & Biotechnology News

In a post-hearing document, Genentech asked the FDA to retain Avastin's breast cancer approval by allowing an updated label as well as a risk evaluation and mitigation strategy and a medication guide. The company also reiterated its plan to undertake a confirmatory study of Avastin plus chemotherapy drug paclitaxel for HER2-negative metastatic breast cancer.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Menlo Park, CA
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ